Vitamin D and the renin-angiotensin system

Vitamin D

Volumn , Issue , 2011, Pages 707-723

  Li, Yan Chun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884793749     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10040-X     Document Type: Chapter

References (149)

1. Reudelhuber T.L. The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:155-159.
2. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87:E1-E9.
3. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275:33238-33243.
4. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
5. Ferrario C.M., Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am. J. Cardiol. 2006, 98:121-128.
6. Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369:1208-1219.
7. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1257-1266.
8. Phillips M.I., Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr. Opin. Investig. Drugs 2002, 3:569-577.
9. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006, 70:1914-1919.
10. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006, 86:747-803.
11. Davisson R.L., Oliverio M.I., Coffman T.M., Sigmund C.D. Divergent functions of angiotensin II receptor isoforms in the brain. J. Clin. Invest. 2000, 106:103-106.
12. Sakai K., Agassandian K., Morimoto S., Sinnayah P., Cassell M.D., Davisson R.L., et al. Local production of angiotensin II in the subfornical organ causes elevated drinking. J. Clin. Invest. 2007, 117:1088-1095.
13. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 2003, 14:274-281.
14. Berry C., Touyz R., Dominiczak A.F., Webb R.C., Johns D.G. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H2337-H2365.
15. Burton J., Quinn T. The amino-acid residues on the C-terminal side of the cleavage site of angiotensinogen influence the species specificity of reaction with renin. Biochim. Biophys. Acta 1988, 952:8-12.
16. Hatae T., Takimoto E., Murakami K., Fukamizu A. Comparative studies on species-specific reactivity between renin and angiotensinogen. Mol. Cell Biochem. 1994, 131:43-47.
17. Yang G., Merrill D.C., Thompson M.W., Robillard J.E., Sigmund C.D. Functional expression of the human angiotensinogen gene in transgenic mice. J. Biol. Chem. 1994, 269:32497-32502.
18. Sielecki A.R., Hayakawa K., Fujinaga M., Murphy M.E., Fraser M., Muir A.K., et al. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989, 243:1346-1351.
19. Danser A.H., Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005, 46:1069-1076.
20. Hackenthal E., Paul M., Ganten D., Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol. Rev. 1990, 70:1067-1116.
21. Bader M., Ganten D. Regulation of renin: new evidence from cultured cells and genetically modified mice [In Process Citation]. J. Mol. Med. 2000, 78:130-139.
22. Mullins J.J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990, 344:541-544.
23. Malmqvist K., Ohman K.P., Lind L., Nystrom F., Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J. Intern. Med. 2002, 252:430-439.
24. Kehoe B., Keeton G.R., Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron. 1986, 44:51-57.
25. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002, 109:1417-1427.
26. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006, 69:105-113.
27. Veniant M., Menard J., Bruneval P., Morley S., Gonzales M.F., Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. 1996, 98:1966-1970.
28. Castrop H., Hocherl K., Kurtz A., Schweda F., Todorov V., Wagner C. Physiology of kidney renin. Physiol. Rev. 2010, 90:607-673.
29. Carey R.M., McGrath H.E., Pentz E.S., Gomez R.A., Barrett P.Q. Biomechanical coupling in renin-releasing cells. J. Clin. Invest. 1997, 100:1566-1574.
30. Holmer S.R., Kaissling B., Putnik K., Pfeifer M., Kramer B.K., Riegger G.A., et al. Beta-adrenergic stimulation of renin expression in vivo. J. Hypertens. 1997, 15:1471-1479.
31. Wagner C., Hinder M., Kramer B.K., Kurtz A. Role of renal nerves in the stimulation of the renin system by reduced renal arterial pressure. Hypertension 1999, 34:1101-1105.
32. Skott O., Briggs J.P. Direct demonstration of macula densa-mediated renin secretion. Science 1987, 237:1618-1620.
33. Peti-Peterdi J., Harris R.C. Macula densa sensing and signaling mechanisms of renin release. J. Am. Soc. Nephrol. 2010, 21:1093-1096.
34. Vander A.J., Geelhoed G.W. Inhibition of renin secretion by angiotensin. II. Proc. Soc. Exp. Biol. Med. 1965, 120:399-403.
35. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 1995, 270:18719-18722.
36. Shricker K., Holmer S., Kramer B.K., Riegger G.A., Kurtz A. The role of angiotensin II in the feedback control of renin gene expression. Pflugers Arch. 1997, 434:166-172.
37. Abel K.J., Gross K.W. Physical characterization of genetic rearrangements at the mouse renin loci. Genetics 1990, 124:937-947.
38. Sigmund C.D., Gross K.W. Structure, expression, and regulation of the murine renin genes. Hypertension 1991, 18:446-457.
39. Pentz E.S., Lopez M.L., Kim H.S., Carretero O., Smithies O., Gomez R.A. Ren1d and Ren2 cooperate to preserve homeostasis: evidence from mice expressing GFP in place of Ren1d. Physiol. Genomics 2001, 6:45-55.
40. Ying L., Morris B.J., Sigmund C.D. Transactivation of the human renin promoter by the cyclic AMP/protein kinase A pathway is mediated by both cAMP-responsive element binding protein-1 (CREB)-dependent and CREB-independent mechanisms in Calu-6 cells. J. Biol. Chem. 1997, 272:2412-2420.
41. Jones C.A., Sigmund C.D., McGowan R.A., Kane-Haas C.M., Gross K.W. Expression of murine renin genes during fetal development. Mol. Endocrinol. 1990, 4:375-383.
42. Jones C.A., Hurley M.I., Black T.A., Kane C.M., Pan L., Pruitt S.C., et al. Expression of a renin/GFP transgene in mouse embryonic, extra-embryonic, and adult tissues. Physiol. Genomics 2000, 4:75-81.
43. Sigmund C.D., Okuyama K., Ingelfinger J., Jones C.A., Mullins J.J., Kane C., et al. Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promoter viral oncogene fusion construct. J. Biol. Chem. 1990, 265:19916-19922.
44. Petrovic N., Black T.A., Fabian J.R., Kane C., Jones C.A., Loudon J.A., et al. Role of proximal promoter elements in regulation of renin gene transcription. J. Biol. Chem. 1996, 271:22499-22505.
45. Adams D.J., Head G.A., Markus M.A., Lovicu F.J., van der Weyden L., Kontgen F., et al. Renin enhancer is critical for control of renin gene expression and cardiovascular function. J. Biol. Chem. 2006, 281:31753-31761.
46. Pan L., Gross K.W. Transcriptional regulation of renin: an update. Hypertension 2005, 45:3-8.
47. Tamura K., Chen Y.E., Horiuchi M., Chen Q., Daviet L., Yang Z., et al. LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc. Natl. Acad. Sci. USA 2000, 97:8513-8518.
48. Shi Q., Gross K.W., Sigmund C.D. Retinoic acid-mediated activation of the mouse renin enhancer. J. Biol. Chem. 2001, 276:3597-3603.
49. Pan L., Black T.A., Shi Q., Jones C.A., Petrovic N., Loudon J., et al. Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J. Biol. Chem. 2001, 276:45530-45538.
50. Pan L., Xie Y., Black T.A., Jones C.A., Pruitt S.C., Gross K.W. An Abd-B class HOX.PBX recognition sequence is required for expression from the mouse Ren-1c gene. J. Biol. Chem. 2001, 276:32489-32494.
51. Pan L., Glenn S.T., Jones C.A., Gronostajski R.M., Gross K.W. Regulation of renin enhancer activity by nuclear factor I and Sp1/Sp3. Biochim. Biophys. Acta 2003, 1625:280-290.
52. Shi Q., Gross K.W., Sigmund C.D. NF-Y antagonizes renin enhancer function by blocking stimulatory transcription factors. Hypertension 2001, 38:332-336.
53. Liu X., Huang X., Sigmund C.D. Identification of a nuclear orphan receptor (Ear2) as a negative regulator of renin gene transcription. Circ. Res. 2003, 92:1033-1040.
54. August P. Initial treatment of hypertension. N. Engl. J. Med. 2003, 348:610-617.
55. Cheung B.M. Blockade of the renin-angiotensin system. Hong Kong Med. J. 2002, 8:185-191.
56. Wood J.M., Schnell C.R., Cumin F., Menard J., Webb R.L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens. 2005, 23:417-426.
57. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-E8.
58. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990, 265:22348-22357.
59. Padmanabhan N., Jardine A.G., McGrath J.C., Connell J.M. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation 1999, 99:2914-2920.
60. Tom B., Dendorfer A., Danser A.H. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?. Int. J. Biochem. Cell Biol. 2003, 35:792-801.
61. Muller D.N., Luft F.C. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol. 2006, 1:221-228.
62. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J. Clin. Pharmacol. 1993, 33:40-45.
63. Roig E., Perez-Villa F., Morales M., Jimenez W., Orus J., Heras M., et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. 2000, 21:53-57.
64. Azizi M., Menard J., Bissery A., Guyenne T.T., Bura-Riviere A., Vaidyanathan S., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 2004, 15:3126-3133.
65. Resnick L.M., Muller F.B., Laragh J.H. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann. Intern. Med. 1986, 105:649-654.
66. Burgess E.D., Hawkins R.G., Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am. J. Hypertens. 1990, 3:903-905.
67. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
68. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci. USA 1997, 94:9831-9835.
69. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nature Genetics 1997, 16:391-396.
70. Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E125-E132.
71. Kong J., Li Y.C. Effect of angiotensin II type I receptor antagonist and angiotensin-converting enzyme inhibitor on vitamin D receptor null mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R255-R261.
72. Kong J., Zhang Z., Li D., Wong K.E., Zhang Y., Szeto F.L., et al. Loss of vitamin D receptor produces polyuria by increasing thirst. J. Am. Soc. Nephrol. 2008, 19:2396-2405.
73. Gunther T., Chen Z.F., Kim J., Priemel M., Rueger J.M., Amling M., et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000, 406:199-203.
74. Li Y.C., Amling M., Pirro A.E., Priemel M., Meuse J., Baron R., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998, 139:4391-4396.
75. Kong J., Li X.J., Gavin D., Jiang Y., Li Y.C. Targeted expression of human vitamin D receptor in the skin promotes the initiation of postnatal hair follicular cycle and rescue the alopecia in vitamin D receptor null mice. J. Invest. Dermatol. 2002, 118:631-638.
76. Kong J., Qiao G., Zhang Z., Liu S.Q., Li Y.C. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008, 74:1577-1581.
77. Kristal-Boneh E., Froom P., Harari G., Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997, 30:1289-1294.
78. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008, 74:170-179.
79. Omdahl J.L., DeLuca H.F. Strontium induced rickets: metabolic basis. Science 1971, 174:949-951.
80. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
81. Palmer H.G., Gonzalez-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001, 154:369-387.
82. Lu X., Farmer P., Rubin J., Nanes M.S. Integration of the NfkappaB p65 subunit into the vitamin D receptor transcriptional complex: identification of p65 domains that inhibit 1,25-dihydroxyvitamin D3-stimulated transcription. J. Cell Biochem. 2004, 92:833-848.
83. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., et al. Increased NF-{kappa}B activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E315-E322.
84. Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
85. De Cesare D., Fimia G.M., Sassone-Corsi P. Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem. Sci. 1999, 24:281-285.
86. Montminy M. Transcriptional regulation by cyclic AMP. Annu. Rev. Biochem. 1997, 66:807-822.
87. Andrisani O.M. CREB-mediated transcriptional control. Crit. Rev. Eukaryot. Gene Expr. 1999, 9:19-32.
88. Brown A.J., Dusso A.S., Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2002, 17(Suppl. 10):10-19.
89. Malluche H.H., Mawad H., Koszewski N.J. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int. 2002, 62:367-374.
90. Qiao G., Kong J., Uskokovic M., Li Y.C. Analogs of 1alpha,25-dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J. Steroid Biochem. Mol. Biol. 2005, 96:59-66.
91. Fryer R.M., Rakestraw P.A., Nakane M., Dixon D., Banfor P.N., Koch K.A., et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron. Physiol. 2007, 106:76-81.
92. Zhang Z., Sun L., Wang Y., Ning G., Minto A.W., Kong J., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008, 73:163-171.
93. Freundlich M., Quiroz Y., Zhang Z., Zhang Y., Bravo Y., Weisinger J.R., et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74:1394-1402.
94. Kong J., Kim G.H., Wei M., Sun T., Li G., Liu S.Q., et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am. J. Pathol. 2010, 177:622-631.
95. Li Y.C. Inhibition of renin: an updated review of the development of renin inhibitors. Curr. Opin. Investig. Drugs 2007, 8:750-757.
96. Zhang Y., Kong J., Ning G., Wong Y., et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am. J. Physiol. Renal Physiol. 2009, 297:F791-F801.
97. Zhang Z., Zhang Y., Ning G., Deb D.K., Kong J., Li Y.C. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl. Acad. Sci. USA 2008, 105:15896-15901.
98. Deb D.K., Sun T., Wong K.E., Zhang Z., Ning G., Zhang Y., et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of Type 2 diabetes. Kidney Int. 2010, In press.
99. Alborzi P., Patel N.A., Peterson C., Bills J.E., Bekele D.M., Bunaye Z., et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008, 52:249-255.
100. Brewster U.C., Perazella M.A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004, 116:263-272.
101. Ruster C., Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006, 17:2985-2991.
102. Ravani P., Malberti F., Tripepi G., Pecchini P., Cutrupi S., Pizzini P., et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009, 75:88-95.
103. Ostchega Y., Yoon S.S., Hughes J., Louis T. Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. NCHS Data Brief No. 3 2008, National Center for Health Statistics, Hyattsville, Maryland.
104. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30:150-156.
105. He J., Klag M.J., Wu Z., Whelton P.K. Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. Stroke 1995, 26:2222-2227.
106. Kunes J., Tremblay J., Bellavance F., Hamet P. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am. J. Hypertens. 1991, 4:422-426.
107. Woodhouse P.R., Khaw K.T., Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J. Hypertens. 1993, 11:1267-1274.
108. Spencer F.A., Goldberg R.J., Becker R.C., Gore J.M. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J. Am. Coll. Cardiol. 1998, 31:1226-1233.
109. Harburg E., Gleibermann L., Roeper P., Schork M.A., Schull W.J. Skin color, ethnicity, and blood pressure I: Detroit blacks. Am. J. Public Health 1978, 68:1177-1183.
110. Klag M.J., Whelton P.K., Coresh J., Grim C.E., Kuller L.H. The association of skin color with blood pressure in US blacks with low socioeconomic status. Jama 1991, 265:599-602.
111. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet 1998, 352:709-710.
112. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am. J. Hypertens. 2007, 20:713-719.
113. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
114. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2007, 167:1159-1165.
115. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
116. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 2008, 168:1174-1180.
117. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
118. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 1995, 8:894-901.
119. Lind L., Wengle B., Wide L., Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am. J. Hypertens. 1989, 2:20-25.
120. Pfeifer M., Begerow B., Minne H.W., Nachtigall D., Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:1633-1637.
121. Wang L., Manson J.E., Buring J.E., Lee I.M., Sesso H.D. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008, 51:1073-1079.
122. Scragg R., Khaw K.T., Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur. J. Clin. Nutr. 1995, 49:640-646.
123. Forman J.P., Bischoff-Ferrari H.A., Willett W.C., Stampfer M.J., Curhan G.C. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 2005, 46:676-682.
124. Tomaschitz A., Pilz S., Ritz E., Grammer T., Drechsler C., Boehm B.O., et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta. 2010, 411:1354-1360.
125. Forman J.P., Williams J.S., Fisher N.D. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010, 55:1283-1288.
126. Petrov V., Lijnen P. Modification of intracellular calcium and plasma renin by dietary calcium in men. Am. J. Hypertens. 1999, 12:1217-1224.
127. Park C.W., Oh Y.S., Shin Y.S., Kim C.M., Kim Y.S., Kim S.Y., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 1999, 33:73-81.
128. Kimura Y., Kawamura M., Owada M., Oshima T., Murooka M., Fujiwara T., et al. Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med. 1999, 38:31-35.
129. Levin A., Li Y.C. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int. 2005, 68:1973-1981.
130. Achinger S.G., Ayus J.C. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int. Suppl. 2005, S37-S42.
131. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
132. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71:31-38.
133. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
134. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003, 349:446-456.
135. Shoji T., Shinohara K., Kimoto E., Emoto M., Tahara H., Koyama H., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 2004, 19:179-184.
136. Tentori F., Hunt W.C., Stidley C.A., Rohrscheib M.R., Bedrick E.J., Meyer K.B., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006, 70:1858-1865.
137. Shoben A.B., Rudser K.D., de Boer I.H., Young B., Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008, 19:1613-1619.
138. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345:851-860.
139. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345:861-869.
140. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345:870-878.
141. Andersen S., Tarnow L., Rossing P., Hansen B.V., Parving H.H. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000, 57:601-606.
142. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358:2433-2446.
143. Zhang Y., Kong J., Deb D.K., Chang A., Li Y.C. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J. Am. Soc. Nephrol. 2010, 21:966-973.
144. Schwarz U., Amann K., Orth S.R., Simonaviciene A., Wessels S., Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998, 53:1696-1705.
145. Kuhlmann A., Haas C.S., Gross M.L., Reulbach U., Holzinger M., Schwarz U., et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal. Physiol. 2004, 286:F526-F533.
146. Mizobuchi M., Morrissey J., Finch J.L., Martin D.R., Liapis H., Akizawa T., et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 2007, 18:1796-1806.
147. Tan X., He W., Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009, 76:1248-1257.
148. de Boer I.H., Ioannou G.N., Kestenbaum B., Brunzell J.D., Weiss N.S. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 2007, 50:69-77.
149. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68:2823-2828.